<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Cardinal Health Inc.（CAH）是一家药品和特种产品的分销商，周二再次上调了其 2026 财年的调整后收益预期，这得益于其五个运营部门的强劲表现和执行力。</p>
<p>在盘前交易中，股价上涨约 1.3%，交易价格为 205.01 美元。</p>
<p>Cardinal Health 的首席执行官 Jason Hollar 表示：“我们团队在战略增长计划上的执行持续带来显著成果，作为我们信心和势头的体现，我们很高兴再次提高对 2026 财年的预期。”</p>
<p>对于 2026 财年，Cardinal Health 现在预计调整后的每股收益至少为 10.00 美元，高于之前的指导区间 9.65 至 9.85 美元。</p>
<p>华尔街分析师平均预计该公司今年每股收益为 9.83 美元。分析师的估计通常不包括特殊项目。</p>
<p>此外，公司预计其特种产品收入将在 2026 财年超过 500 亿美元，标志着三年内 16% 的年复合增长率（CAGR）。根据该公司的说法，特种分销的强劲需求、MSO 平台的扩展以及预计在 2026 财年生物制药解决方案中超过 30% 的收入增长将有利于收入增长。</p>
<p>该公司表示，计划在第 44 届摩根大通医疗会议上重点介绍其战略增长举措的重大进展。</p>
<p>此外，Cardinal Health 确认了其所有受 2026 年医疗保险药品价格谈判计划影响的品牌药品的制造商分销服务协议的过渡。</p>
<p>该公司计划在 2 月 5 日的第二季度财报电话会议上提供更多细节和更新。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

卡地纳健康

<p>卡地纳健康公司（Cardinal Health Inc.，股票代码：CAH）已将其 2026 财年的调整后每股收益预期上调至至少 10.00 美元，高于之前的 9.65 至 9.85 美元的范围，这得益于其五个运营部门的强劲表现。该公司的股票在盘前交易中上涨了 1.3%。卡地纳健康还预计，2026 财年的专业收入将超过 500 亿美元，这主要是由于强劲的需求和生物制药解决方案的显著增长。更多细节将在 2 月 5 日的第二季度财报电话会议上提供</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Cardinal Health Inc. (CAH), a distributor of pharmaceuticals and specialty products, on Tuesday lifted its fiscal 2026 adjusted earnings outlook again, driven by strong performance and execution across its five operating segments.</p>
<div class="lb-trans"><p>Cardinal Health Inc.（CAH）是一家药品和特种产品的分销商，周二再次上调了其 2026 财年的调整后收益预期，这得益于其五个运营部门的强劲表现和执行力。</p>
</div><p>In pre-market activity, the shares were gaining around 1.3 percent, trading at $205.01.</p>
<div class="lb-trans"><p>在盘前交易中，股价上涨约 1.3%，交易价格为 205.01 美元。</p>
</div><p>Jason Hollar, CEO of Cardinal Health, stated, &#34;Our team's execution against our strategic growth plan continues to deliver meaningful results, and as a demonstration of our confidence and momentum, we are pleased to again raise our expectations for fiscal year 2026.&#34;</p>
<div class="lb-trans"><p>Cardinal Health 的首席执行官 Jason Hollar 表示：“我们团队在战略增长计划上的执行持续带来显著成果，作为我们信心和势头的体现，我们很高兴再次提高对 2026 财年的预期。”</p>
</div><p>For fiscal 2026, Cardinal Health now expects adjusted earnings per share of at least $10.00, higher than its prior guidance range of $9.65 to $9.85.</p>
<div class="lb-trans"><p>对于 2026 财年，Cardinal Health 现在预计调整后的每股收益至少为 10.00 美元，高于之前的指导区间 9.65 至 9.85 美元。</p>
</div><p>The Wall Street analysts on average expect the company to report earnings of $9.83 per share for the year. Analysts' estimates typically exclude special items.</p>
<div class="lb-trans"><p>华尔街分析师平均预计该公司今年每股收益为 9.83 美元。分析师的估计通常不包括特殊项目。</p>
</div><p>Further, the company projects that its Specialty revenues will surpass $50 billion in fiscal 2026, marking a 16 percent compounded annual growth rate or CAGR over three years. According to the firm, robust demand across specialty distribution, the expansion of its MSO platforms and over 30 percent anticipated revenue growth in BioPharma Solutions in fiscal 2026 will benefit the revenue growth.</p>
<div class="lb-trans"><p>此外，公司预计其特种产品收入将在 2026 财年超过 500 亿美元，标志着三年内 16% 的年复合增长率（CAGR）。根据该公司的说法，特种分销的强劲需求、MSO 平台的扩展以及预计在 2026 财年生物制药解决方案中超过 30% 的收入增长将有利于收入增长。</p>
</div><p>The firm said it plans to highlight significant progress with its strategic growth initiatives during the 44th Annual J.P. Morgan Healthcare Conference.</p>
<div class="lb-trans"><p>该公司表示，计划在第 44 届摩根大通医疗会议上重点介绍其战略增长举措的重大进展。</p>
</div><p>In addition, Cardinal Health confirmed the transition of its manufacturer distribution service agreements for all branded pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation Program.</p>
<div class="lb-trans"><p>此外，Cardinal Health 确认了其所有受 2026 年医疗保险药品价格谈判计划影响的品牌药品的制造商分销服务协议的过渡。</p>
</div><p>The company is scheduled to provide further details and updates on its upcoming second quarter earnings call on February 5.</p>
<div class="lb-trans"><p>该公司计划在 2 月 5 日的第二季度财报电话会议上提供更多细节和更新。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

卡地纳健康将 2026 财年的调整后收益预期上调至高于市场水平